# Sherko Kümmel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sherko-kummel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21,794 |
| Field | Breast Cancer Treatment Studies |
| h-index | 59 |
| i10-index | 178 |
| Last Known Institution | Kliniken Essen-Mitte |
| OpenAlex ID | https://openalex.org/A5108747112 |
| Works | 515 |

## Researcher papers

- [Pembrolizumab for Early Triple-Negative Breast Cancer](https://scholariq.org/papers/pembrolizumab-for-early-triple-negative-breast-cancer/)
- [Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy](https://scholariq.org/papers/tumour-infiltrating-lymphocytes-and-prognosis-in-different-subtypes-of-breast/)
- [Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial](https://scholariq.org/papers/neoadjuvant-carboplatin-in-patients-with-triple-negative-and-her2-positive-early/)
- [Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers](https://scholariq.org/papers/tumor-infiltrating-lymphocytes-and-response-to-neoadjuvant-chemotherapy-with-or/)
- [A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study](https://scholariq.org/papers/a-randomised-phase-ii-study-investigating-durvalumab-in-addition-to-an/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)

## Researcher university

- [Kliniken Essen-Mitte](https://scholariq.org/institutions/kliniken-essen-mitte/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.